silybin has been researched along with 2019 Novel Coronavirus Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alam, MJ; Alreshidi, M; Saeed, A; Saeed, M | 1 |
| Dasgupta, N; Haque, S; Hussain, A; Mishra, BN; Singh, V; Srivastava, R; Tripathi, S; Unni, S | 1 |
| Cimino, F; Giofrè, SV; Molonia, MS; Muscarà , C; Saija, A; Speciale, A | 1 |
| Borah, S; Jaiswal, S; Kaur, G; Mukherjee, S; Sharma, AK; Sharma, D; Sharma, N | 1 |
4 other study(ies) available for silybin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Computational hunting of natural active compounds as an alternative for Remdesivir to target RNA-dependent polymerase.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Biological Products; Catalytic Domain; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; Curcumin; Databases, Protein; Drug Discovery; Drug Evaluation, Preclinical; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Molecular Docking Simulation; Phytochemicals; Protein Binding; SARS-CoV-2; Silybin | 2021 |
Silybin B and Cianidanol Inhibit M
Topics: Antiviral Agents; Catechin; COVID-19; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; SARS-CoV-2; Silybin; Spike Glycoprotein, Coronavirus | 2021 |
Silibinin as potential tool against SARS-Cov-2: In silico spike receptor-binding domain and main protease molecular docking analysis, and in vitro endothelial protective effects.
Topics: Coronavirus 3C Proteases; COVID-19; Endothelial Cells; Humans; Molecular Docking Simulation; Peptide Hydrolases; SARS-CoV-2; Silybin; Spike Glycoprotein, Coronavirus | 2021 |
Flavan-based phytoconstituents inhibit Mpro, a SARS-COV-2 molecular target,
Topics: Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protease Inhibitors; SARS-CoV-2; Silybin | 2022 |